Anthem Joins Other Large Insurers In ‘Artificial Pancreas’ Coverage
Executive Summary
The largest US insurers have now all agreed to cover "artificial pancreas" system. Medtronic’s MiniMed 670G became the first fully closed-loop insulin pump/continuous glucose monitor system to win FDA approval in September 2016.
You may also be interested in...
Medtronic Enters New Outcomes-Based Insulin Pump Deal With Aetna
The device-maker will be on the hook to provide rebates to the health insurer if its self-adjusting insulin pumps don't maintain patients in appropriate glucose ranges, under a newly inked agreement. Medtronic already has a similar arrangement with UnitedHealthcare.
Market Intel: Advent Of Artificial Pancreas Tech To Galvanize Fast-Growing Diabetes Market
The global diabetes management devices market is expected to exceed $11.2bn by 2020, driven largely by the rising diabetes epidemic. This, in turn, is fueling significant innovation such as next-generation, automated artificial pancreas systems and miniaturized, less-invasive wireless technologies that can continuously track and analyze glucose levels in real-time. This feature looks more closely at these and other potentially groundbreaking new technologies, as well as the competitive landscape of the two major product segments – insulin pumps and blood glucose monitors.
US FDA Approves First 'Artificial Pancreas' In Medtronic's MiniMed 670G
The hybrid closed-loop automated insulin delivery system, the first closed-loop system approved anywhere in the world, automatically monitors glucose and provides appropriate basal insulin doses in people with type 1 diabetes.